Molecular profiling of breast cancer

Surgical Oncology Clinics of North America

Volumn 23, Issue 3, 2014, Pages 451-462

  Cyr, Amy E ^a   Margenthaler, Julie A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Genome; Molecular diagnostics; Molecular profiling; Prognostication

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL; METHOTREXATE; TAMOXIFEN; TRASTUZUMAB;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; DRUG EFFICACY; DRUG INDICATION; GENETIC ANALYSIS; GENETIC RISK; HUMAN; INTRADUCTAL CARCINOMA; MOLECULAR DIAGNOSIS; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PREDICTION; QUALITY ADJUSTED LIFE YEAR; REVIEW; TREATMENT PLANNING; TUMOR GENE; TUMOR INVASION; BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION PROFILING; GENETICS; METABOLISM; PATHOLOGY; PROGNOSIS;

BREAST NEOPLASMS; CARCINOMA, INTRADUCTAL, NONINFILTRATING; FEMALE; GENE EXPRESSION PROFILING; HUMANS; PROGNOSIS;

EID: 84901676155     PISSN: 10553207     EISSN: 15585042     Source Type: Journal    
DOI: 10.1016/j.soc.2014.03.004     Document Type: Review

References (64)

1. Reis-Filho J.S., Weigelt B., Fumagalli D., et al. Molecular profiling: moving away from tumor philately. Sci Transl Med 2010, 2:47ps43.
2. Sotiriou C., Pusztai L. Gene-expression signatures in breast cancer. NEngl J Med 2009, 360:790-800.
3. Weigelt B., Baehner F.L., Reis-Filho J.S. The contribution of gene expression profiling to breast cancer classification, prognostication, and prediction: a retrospective of the last decade. JPathol 2010, 220:263-280.
4. Iwamoto T., Pusztai L. Predicting prognosis of breast cancer with gene signatures: are we lost in a sea of data?. Genome Med 2010, 2:81.
5. Perou C.M., Sorlie T., Eisen M.B., et al. Molecular portraits of human breast tumours. Nature 2000, 406:747-752.
6. Sorlie T., Perou C.M., Tibshirani R., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874.
7. Fan C., Oh D.S., Wessels L., et al. Concordance among gene-expression-based predictors for breast cancer. NEngl J Med 2006, 355:560-569.
8. Hu Z., Fan C., Oh D.S., et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006, 7:96.
9. Voduc K.D., Cheang M.C., Tyldesley S., et al. Breast cancer subtypes and the risk of local and regional relapse. JClin Oncol 2010, 28:1684-1691.
10. Reis-Filho J.S., Pusztai L. Gene expression profiling in breast cancer: classification, prognostication, and prediction. Lancet 2011, 378:1812-1823.
11. Prat A., Ellis M.J., Perou C.M. Practical implications of gene-expression-based assays for breast oncologists. Nature 2012, 9:48-57.
12. Reis-Filho J.S., Tutt A.N. Triple negative tumours: a critical review. Histopathology 2008, 52:108-118.
13. Schwartz G.F., Bartelink H., Burstein H.J., et al. Adjuvant therapy in Stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Breast J 2012, 118:2031-2038.
14. Carey L.A., Perou C.M., Livasy C.A., et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295:2492-2502.
15. Prat A., Adamo B., Cheang M.C., et al. Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. Oncologist 2013, 18:123-133.
16. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 2001, 344:783-792.
17. Paik S. Development and clinical utility of a 21-gene recurrence score prognostic assay in patients with early breast cancer treated with tamoxifen. Oncologist 2007, 12:631-635.
18. Van de Vijver M.J., He Y.D., Van't Veer L.J., et al. Agene-expression signature as a predictor of survival in breast cancer. NEngl J Med 2002, 347:1999-2009.
19. Buyse M., Loi S., Van't Veer L., et al. Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. JNatl cancer Inst 2006, 98:1183-1192.
20. Mook S., Schmidt M.K., Weigelt B., et al. The 70-gene prognosis signature predicts early metastasis in breast cancer patients between 55 and 70 years of age. Ann Oncol 2010, 21:717-722.
21. Mook S., Knauer M., Bueno-de-Mesquita J.M., et al. Metastatic potential of T1 breast cancer can be predicted by the 70-gene MammaPrint signature. Ann Surg Oncol 2010, 17:1406-1413.
22. Nielsen T.O., Parker J.S., Leung S., et al. Acomparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16:5222-5232.
23. Chia S.K., Bramwell V.H., Tu D., et al. A50-gene intrinsic subtype classifier for prognosis and prediction of benefit from adjuvant tamoxifen. Clin Cancer Res 2012, 18:4465-4472.
24. Dowsett M., Lopez-Knowles E., Sidhu K. Comparison of PAM50 risk of recurrence score with oncotypeDx and IHC4 for predicting risk of distant recurrence after endocrine therapy. JClin Oncol 2013, 31:2783-2790.
25. Fisher B., Anderson S., Bryant J., et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. NEngl J Med 2002, 347:1233-1241.
26. Benson J.R., Wishart G.C. Predictors of recurrence for ductal carcinoma in situ after breast-conserving surgery. Lancet Oncol 2013, 14:e348-e357.
27. Carlson R.W., Allred D.C., Anderson B.O., et al. NCCN clinical practice guidelines in oncology: breast cancer 2008, National Comprehensive Cancer Network, Fort Washington (PA), Available at:, Accessed August 23, 2013. http://www.nccnorg.
28. Silverstein M.J. The University of Southern California/Van Nuys prognostic index for ductal carcinoma in situ of the breast. Am J Surg 2003, 186:337-343.
29. Gauthier M.L., Berman H.K., Miller C., et al. Abrogated response to cellular stress identifies DCIS associated with subsequent tumor events and defines basal-like breast tumours. Cancer Cell 2007, 12:479-491.
30. Solin L., Gray R., Baehner F., et al. Aquantitative multigene RT-PCR assay for predicting recurrence risk after surgical excision alone without irradiation for ductal carcinoma in situ (DCIS): a prospective validation study of the DCIS Score from the ECOG E5194. JNatl Cancer Inst 2013, 105:701-710.
31. Hughes L.L., Wang M., Page D.L., et al. Local excision alone without irradiation for ductal carcinoma in situ of the breast: a trial of the Eastern Cooperative Oncology Group. JClin Oncol 2009, 27:5319-5324.
32. National Cancer Institute Clinical alert 1988, National Cancer Institute, Bethesda (MD).
33. Dignam J.J., Dukic V., Anderson S.J., et al. Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer. Breast Cancer Res Treat 2009, 116:595-602.
34. Boyages J., Taylor R., Chua B., et al. Arisk index for early node-negative breast cancer. Br J Surg 2006, 93:564-571.
35. Paik S., Shak S., Tang G., et al. Amultigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. NEngl J Med 2004, 351:2817-2826.
36. Habel L.A., Shak S., Jacobs M.K., et al. Apopulation-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients. Breast Cancer Res 2006, 8:R25.
37. Paik S., Tang G., Shak S., et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. JClin Oncol 2006, 24:3726-3734.
38. Harris L., Fritsche H., Mennel R., et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. JClin Oncol 2007, 25:5287-5312.
39. NCCN clinical practice guidelines in oncology: breast cancer. Available at:. Accessed August 24-25, 2013. http://www.nccn.org/professionals/physician_gls/pdf/breast.pdf.
40. Goldhirsch A., Wood W.C., Coates A.S. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 2011, 22:1736-1747.
41. Zujewski J.A., Kamin L. Trial assessing individualized options for treatment for breast cancer: the TAILORx trial. Future Oncol 2008, 4:603-610.
42. Mamounas E.P., Tang G., Fisher B., et al. Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20. JClin Oncol 2010, 28:1677-1683.
43. Van't Veer L.J., Dai H., Van de Vijver M.J., et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
44. Knauer M., Mook S., Rutgers E.J., et al. The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 2010, 120:655-661.
45. Rutgers E., Piccart-Gebhart M.J., Bogaerts J., et al. The EORTC 10041/BIG 03-04 MINDACT trial is feasible: results of the pilot phase. Eur J Cancer 2011, 47:2742-2749.
46. Parker J.S., Mullins M., Cheang M.C., et al. Supervised risk predictor of breast cancer based on intrinsic subtypes. JClin Oncol 2009, 27:1160-1167.
47. Dent D.M. Axillary lymphadenectomy for breast cancer. Arch Surg 1996, 131:1125-1127.
48. Fisher B., Jeong J.H., Anderson S., et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by radiation. NEngl J Med 2002, 347:567-575.
49. Tan L.K., Giri D., Hummer A.J., et al. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. JClin Oncol 2008, 26:1803-1809.
50. Albain K.S., Barlow W.E., Shak S., et al. Prognostic and predictive value of the 21-gene recurrence score assay in a randomized trial of chemotherapy for postmenopausal, node-positive, estrogen receptor-positive breast cancer. Lancet Oncol 2010, 11:55-65.
51. Dowsett M., Cuzick J., Wale C., et al. Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study. JClin Oncol 2010, 28:1829-1834.
52. Mook S., Schmidt M.K., Viale G., et al. The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 2009, 116:295-302.
53. Mamounas EP, Tang G, Paik S, etal. The 21-gene recurrence score predicts risk of loco-regional recurrence in node (+), ER (+) breast cancer after adjuvant chemotherapy and tamoxifen: results from the NSABP B-28. Abstract #2, Social of Surgical Oncology Annual Cancer Symposium. 2013.
54. Prat A., Parker J.S., Fan C., et al. Concordance among gene-expression based predictors for ER-positive breast cancer treated with adjuvant tamoxifen. Ann Oncol 2012, 23:2866-2873.
55. Goncalves R., Bose R. Using multigene tests to select treatment for early-stage breast cancer. JNatl Compr Canc Netw 2013, 11:174-182.
56. Ademuyiwa F.O., Miller A., O'Connor T., et al. The effects of Oncotype DX recurrence scores on chemotherapy utilization on a multi-institutional breast cancer cohort. Breast Cancer Res Treat 2011, 126:797-802.
57. Asad J., Jacobson A.F., Estabrook A., et al. Does Oncotype DX recurrence score affect the management of patients with early-stage breast cancer?. Am J Surg 2008, 196:527-529.
58. Klang S.H., Hammerman A., Liebermann N., et al. Economic implications of 21-gene breast cancer risk assay from the perspective of an Israeli-managed health care organization. Value Health 2010, 13:381-387.
59. Chen C., Dhanda R., Tseng W.Y., et al. Evaluating use characteristics for the Oncotype dx 21-gene recurrence score and concordance with chemotherapy use in early-stage breast cancer. JOncol Pract 2013, 9:182-187.
60. Lo S.S., Mumby P.B., Norton J., et al. Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. JClin Oncol 2010, 28:1671-1677.
61. Bueno-de-Mesquita J.M., van Harten W.H., Retel V.P., et al. Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 2007, 8:1079-1087.
62. Hornberger J., Chien R., Krebs K., et al. US insurance program's experience with a multigene assay for early-stage breast cancer. JOncol Pract 2011, 7:e38s-e45s.
63. Lamond N.W., Skedgel C., Rayson D., et al. Cost-utility of the 21-gene recurrence score assay in node-negative and node-positive breast cancer. Breast Cancer Res Treat 2012, 133:1115-1123.
64. Available at:. Accessed August 27, 2013. http://www.Clinicaltrials.gov.